Effect of Memantine on Cognitive Impairment in Patients With Epilepsy

Assiut University

Status and phase: Completed; Phase 1

Conditions: Epilepsy

Treatments: Drug: Memantine Hydrochloride; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT04417543

Memantine in epilepsy

Details and patient eligibility

About

Evaluate the efficacy of memantine on improving the cognitive impairment in patient with epilepsy

Full description

Epilepsy is a complex disorder, which involves much more than seizures, encompassing a range of associated comorbid health conditions that can have significant health and quality-of-life implications. Of these comorbidities, cognitive impairment is one of the most common and distressing aspects of epilepsy.

Excito-toxicity, mediated by glutamate acting on N-methyl-D-aspartate (NMDA) receptors in the hippocampus, can cause memory dysfunction in epilepsy .

Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor . It also has antioxidant property and increases production of brain derived neurotropic factor (BDNF)

Enrollment: 100 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with idiopathic epilepsy.
• Normal brain imaging (CT brain).
• Patients on anti epileptic drugs more than 6 months.
• No more than two fits per month.
• Score of Mini mental state examination (10-24), mild and moderate cognitive impairment.
• No other medical disorders.

Exclusion criteria

• Progressive neurological diseases.
• Abnormal brain imaging (CT brain).
• More than two fits per month.
• Patients with severe cognitive impairment, score of MMSE less than10.
• Patients with severe medical disorders

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

100 participants in 2 patient groups, including a placebo group

Memantine hydrochloride group

Active Comparator group

Description:

included 50 patients who received memantine

Treatment:

Drug: Memantine Hydrochloride

Placebo group

Placebo Comparator group

Description:

included 50 patients who received placebo

Treatment:

Drug: Placebo